TNDM
Tandem Diabetes Care·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TNDM
Tandem Diabetes Care, Inc.
A global insulin delivery and diabetes technology company based in San Diego, California
Healthcare Equipment and Supplies
01/27/2006
11/14/2013
NASDAQ Stock Exchange
2,650
12-31
Common stock
12400 High Bluff Drive, San Diego, California 92130
--
Tandem Diabetes Care, Inc., is a medical device company specializing in the design, development and sale of products for patients with insulin-dependent diabetes. Tianteng was originally established in Colorado on January 27, 2006 as Ferrud Corporation. In order to change the company name to Tianteng Diabetes Therapeutics, it was reorganized in Delaware on January 7, 2008, and the company also moved to Delaware. The company designs and sells its flagship product, the t: slim insulin infusion system, also known as t: slim, which is developed on the basis of a proprietary technology platform and a unique consumer-centric approach. The technology platform has a patented micro-infusion technology, which is a miniature pumping mechanism that extracts insulin from a deformable bag placed in the pump cover, instead of relying on syringe and piston mechanisms. The system also has an easy-to-operate software architecture, a color touch screen, and a micro-USB interface that can support battery charging and t: connection, as well as data management application software. The company's innovative approach to product design and R&D is also customer-centric and based on market research, as the company believes that users are the primary decision makers for purchasing insulin injection cartridges.
Earnings Call
Q1/2025
Estimate EPS-0.61
Actual EPS-1.97
Estimate Revenue220.22M
Actual Revenue234.40M
Contradictions Revealed: Analyzing Financial Impacts of Pharmacy Strategy and Salesforce Expansion in 2025 Q1
May 06,2025 10:34
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.4
Actual EPS-0.78
Estimate Revenue238.39M
Actual Revenue240.68M
Tandem Diabetes Care's 2025 Q2 Earnings Call: Unpacking Contradictions in CMS Proposals, Pharmacy Strategies, and Renewal Growth
Aug 11,2025 03:21
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TNDM has released its 2025 Q3 earnings. EPS was reported at -0.31, versus the expected -0.34, beating expectations. The chart below visualizes how TNDM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TNDM has released its 2025 Q3 earnings report, with revenue of 249.25M, reflecting a YoY change of 2.17%, and net profit of -21.16M, showing a YoY change of 8.97%. The Sankey diagram below clearly presents TNDM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
